title: Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation.
abstract: Glucagon-like peptide1 (GLP-1) is secreted from Langerhans cells in response to oral nutrient intake. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a new class of incretin-based anti-diabetic drugs. They function to stimulate insulin secretion while suppressing glucagon secretion. GLP-1-based therapies are now well established in the management of type 2 diabetes mellitus (T2DM), and recent literature has suggested potential applications of these drugs in the treatment of obesity and for protection against cardiovascular and neurological diseases. As we know, along with change in lifestyles, the prevalence of non-alcoholic fatty liver disease (NAFLD) in China is rising more than that of viral hepatitis and alcoholic fatty liver disease, and NAFLD has become the most common chronic liver disease in recent years. Recent studies further suggest that GLP-1RAs can reduce transaminase levels to improve NAFLD by improving blood lipid levels, cutting down the fat content to promote fat redistribution, directly decreasing fatty degeneration of the liver, reducing the degree of liver fibrosis and improving inflammation. This review shows the NAFLD-associated effects of GLP-1RAs in animal models and in patients with T2DM or obesity who are participants in clinical trials.
authors.affiliation: Xing-Chun Wang, Shen Qu, Department of Endocrinology and Metabolism, Shanghai 10 People's Hospital, Tongji University, Shanghai 200072, China.
authors.forename: Xing-Chun
authors.initials: XC
authors.lastname: Wang
authors.affiliation: Xing-Chun Wang, Shen Qu, Department of Endocrinology and Metabolism, Shanghai 10 People's Hospital, Tongji University, Shanghai 200072, China.
authors.forename: Aaron M
authors.initials: AM
authors.lastname: Gusdon
authors.affiliation: Xing-Chun Wang, Shen Qu, Department of Endocrinology and Metabolism, Shanghai 10 People's Hospital, Tongji University, Shanghai 200072, China.
authors.forename: Huan
authors.initials: H
authors.lastname: Liu
authors.affiliation: Xing-Chun Wang, Shen Qu, Department of Endocrinology and Metabolism, Shanghai 10 People's Hospital, Tongji University, Shanghai 200072, China.
authors.forename: Shen
authors.initials: S
authors.lastname: Qu
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D000067757:Glucagon-Like Peptide-1 Receptor; D006505:Hepatitis / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D054795:Incretins / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008103:Liver Cirrhosis / Q000097:blood / Q000175:diagnosis / Q000517:prevention & control; D065626:Non-alcoholic Fatty Liver Disease / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D009765:Obesity / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D018027:Receptors, Glucagon / Q000819:agonists* / Q000378:metabolism; D012307:Risk Factors; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D054795:Incretins; D008055:Lipids; D018027:Receptors, Glucagon
keywords: Fat content; Glucagon-like peptide-1 receptor agonists; Inflammation; Liver function; Non-alcoholic fatty liver disease